Mahalingam, Devalingam
Chen, Siqi
Xie, Ping
Loghmani, Houra
Heineman, Thomas
Kalyan, Aparna
Kircher, Sheetal
Helenowski, Irene B.
Mi, Xinlei
Maurer, Victoria
Coffey, Matt
Mulcahy, Mary
Benson, Al-
Zhang, Bin http://orcid.org/0000-0002-6631-7647
Funding for this research was provided by:
Oncolytics Biotech
Merck
Article History
Received: 15 February 2023
Revised: 7 June 2023
Accepted: 21 June 2023
First Online: 13 July 2023
Competing interests
: DM received research funding Oncolytics Biotech and drug support from Merck. HL, TH and MC are employees of Oncolytics Biotech.
: This study was conducted upon approval of the Institutional Review Board (IRB) at Northwestern University, Chicago, IL on 5/02/2018 (IRB number: STU00207577) and in accordance with current U.S. Food and Drug Administration (FDA) regulations, the International Conference on Harmonisation (ICH), Good Clinical Practices (GCPs), the Declaration of Helsinki, and local ethical and legal requirements. All patients signed a written informed consent before the conduct of any study procedures and after a full explanation of the study to the patient by the study investigator.